Price
Target price
€25.20
€25.20
-1.530%
-0.4
-1.530%
€34.81
29.05.26 / Tradegate
WKN: A1W2RM / Symbol: AGIO / Name: Agios / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Agios Pharmaceuticals Inc. Stock
We can see a decrease in the price for Agios Pharmaceuticals Inc.. Compared to yesterday it has lost -€0.400 (-1.530%).
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Agios Pharmaceuticals Inc..
As a result the target price of 34 € shows a positive potential of 34.92% compared to the current price of 25.2 € for Agios Pharmaceuticals Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Agios Pharmaceuticals Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Agios Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agios Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc. | -1.530% | 3.279% | 4.132% | -10.000% | 8.621% | 0.800% | -46.165% |
| Ligand Pharmaceuticals | -2.940% | 7.447% | 1.508% | 126.966% | 21.687% | 190.647% | 109.848% |
| United Therapeutics | -1.000% | -0.863% | -0.720% | 72.825% | 12.965% | 143.788% | 215.490% |
| Ionis Pharmaceuticals Inc. | 0.780% | 3.081% | 2.341% | 122.758% | -3.502% | 72.171% | 114.664% |
Comments
Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $41.00 to $40.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target lowered by Truist Financial Corporation from $39.00 to $36.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
Agios Pharmaceuticals (AGIO) had its price target lowered by Bank of America Corporation from $44.00 to $41.00. They now have a "buy" rating on the stock.
Show more
Ratings data for AGIO provided by MarketBeat
News
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances
Key Points
- Interested in Agios Pharmaceuticals, Inc.? Here are five stocks we like better.
- Agios said its rare hematology strategy is gaining momentum, pointing to a “very strong” early launch
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) rose by 11.2% this week, putting the stock into positive territory for the year. The move comes after a well-received first-quarter earnings report
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Agios Pharmaceuticals (NASDAQ: AGIO) was a standout stock in the healthcare sector on Hump Day. Investors eagerly snapped up the company's shares after it unveiled its latest quarterly earnings